Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Gordon

Showing results (151-160 of 200) with videos related to

Pageof 20
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005
Molecular determinants of cetuximab efficacyDaniel Vallböhmer, Wu Zhang, Michael Gordon, et al.
Addiction (Abingdon, England)|February 28, 2017
Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorderSean M Murphy, Daniel Polsky, Joshua D Lee, et al.
The American Journal of Tropical Medicine and Hygiene|March 13, 2019
Global Outbreaks and Origins of a Chikungunya Virus Variant Carrying Mutations Which May Increase Fitness for <i>Aedes aegypti</i>: Revelations from the 2016 Mandera, Kenya OutbreakIrina Maljkovic Berry, Fredrick Eyase, Simon Pollett, et al.
Clinical Colorectal Cancer|August 16, 2005
Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancerWu Zhang, Jan Stoehlmacher, David J Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximabWu Zhang, Michael Gordon, Anne M Schultheis, et al.
Cancer Chemotherapy and Pharmacology|August 27, 2013
A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumorsKyriakos P Papadopoulos, Howard A Burris, Michael Gordon, et al.
Journal for Immunotherapy of Cancer|February 6, 2023
Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumorsAnthony W Tolcher, Michael Gordon, Kathleen M Mahoney, et al.
Journal of Biomedical Optics|March 29, 2014
Simultaneous multiplane imaging of human ovarian cancer by volume holographic imagingGabriel V Orsinger, Jennifer M Watson, Michael Gordon, et al.
Diabetes Care|January 10, 2012
Potential implications of coronary artery calcium testing for guiding aspirin use among asymptomatic individuals with diabetesMichael Gordon Silverman, Michael J Blaha, Matthew J Budoff, et al.
Plant Direct|July 17, 2023
Knockout of floral and meiosis genes using CRISPR/Cas9 produces male-sterility in Eucalyptus without impacts on vegetative growthMichael F Nagle, Surbhi S Nahata, Bahiya Zahl, et al.
Pageof 20

Showing results (151-160 of 200) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005
Molecular determinants of cetuximab efficacyDaniel Vallböhmer, Wu Zhang, Michael Gordon, et al.
Addiction (Abingdon, England)|February 28, 2017
Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorderSean M Murphy, Daniel Polsky, Joshua D Lee, et al.
The American Journal of Tropical Medicine and Hygiene|March 13, 2019
Global Outbreaks and Origins of a Chikungunya Virus Variant Carrying Mutations Which May Increase Fitness for <i>Aedes aegypti</i>: Revelations from the 2016 Mandera, Kenya OutbreakIrina Maljkovic Berry, Fredrick Eyase, Simon Pollett, et al.
Clinical Colorectal Cancer|August 16, 2005
Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancerWu Zhang, Jan Stoehlmacher, David J Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximabWu Zhang, Michael Gordon, Anne M Schultheis, et al.
Cancer Chemotherapy and Pharmacology|August 27, 2013
A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumorsKyriakos P Papadopoulos, Howard A Burris, Michael Gordon, et al.
Journal for Immunotherapy of Cancer|February 6, 2023
Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumorsAnthony W Tolcher, Michael Gordon, Kathleen M Mahoney, et al.
Journal of Biomedical Optics|March 29, 2014
Simultaneous multiplane imaging of human ovarian cancer by volume holographic imagingGabriel V Orsinger, Jennifer M Watson, Michael Gordon, et al.
Diabetes Care|January 10, 2012
Potential implications of coronary artery calcium testing for guiding aspirin use among asymptomatic individuals with diabetesMichael Gordon Silverman, Michael J Blaha, Matthew J Budoff, et al.
Plant Direct|July 17, 2023
Knockout of floral and meiosis genes using CRISPR/Cas9 produces male-sterility in Eucalyptus without impacts on vegetative growthMichael F Nagle, Surbhi S Nahata, Bahiya Zahl, et al.
Pageof 20